Updates in Cholangiocarcinoma
This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.
Dr Baretti on Mitigating Toxicities Associated With FGFR Inhibition in Cholangiocarcinoma
November 13th 2023Marina Baretti, MD, discusses some common adverse effects associated with FGFR inhibition in patients with cholangiocarcinoma, as well as strategies to mitigate these AEs in clinical practice.
Dr Baretti on the Mechanisms of Resistance Associated With FGFR2+ Cholangiocarcinoma
November 8th 2023Marina Baretti, MD, discusses innate and acquired mechanisms of resistance in patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements.
Dr Baretti on the Utility of FGFR Inhibitors in FGFR2+ Intrahepatic Cholangiocarcinoma
November 3rd 2023Marina Baretti, MD, discusses the evolving utility of FGFR inhibitors in the treatment of patients with unresectable, advanced, or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
